Articles tagged with Prostate Cancer
A new study suggests that digital rectal examination (DRE) is not a reliable screening tool for early prostate cancer detection. Researchers found that DRE missed many cancers in their early stages, with only 3 out of 57 suspicious cases detected. This method was compared to PSA testing, which detected four times more prostate cancers.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
Researchers found that patients receiving salvage radiation therapy (sRT) with PSA levels above 0.25 ng/mL had a 50% higher risk of death compared to those with lower PSA levels. The study suggests delaying sRT until PSA levels exceed 0.30 ng/mL may increase mortality risk.
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.
Researchers from Northwestern University discuss the multifaceted tumorigenic functions of EZH2, including its role in regulating translation and coactivating transcription. This new understanding may provide novel insights into advancing EZH2-targeting strategies for prostate cancer patients.
A recent study has identified nine new genetic variants that increase the risk of prostate cancer in men of African descent, including a variant linked to aggressive forms. The findings can be used to refine polygenic risk scores and identify high-risk patients for earlier screenings.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Active surveillance for managing low-risk prostate cancer is increasing nationally, but wide variation persists across practices and practitioners. The study highlights the need for continued progress to minimize overtreatment and improve the benefit-to-harm ratio of national efforts.
A new AR system using HoloLens enables doctors to perform transperineal prostate interventions with high accuracy and flexibility. The system provides a 3D immersive experience, allowing doctors to guide needles to their target with ease.
Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.
A new mathematical model has been developed to optimize treatment for prostate cancer, showing promising results in eliminating cancer cells. The model explores different therapeutic strategies, including single drugs and drug combinations, and suggests that alternating therapies could significantly improve cancer treatment.
A new machine learning model combines fusion gene profiling, serum PSA level, and Gleason score to predict prostate cancer recurrence with improved accuracy. The model outperformed clinical data alone and provided valuable insights into the mechanism of disease progression.
Men with non-metastatic castration-resistant prostate cancer treated with enzalutamide experienced sharp reductions in PSA levels, leading to improved survival rates. A 50% decrease in PSA was associated with lower risk of metastases and longer survival time.
Researchers at the University of East Anglia have developed a new blood test to detect prostate cancer with 94% accuracy. The Prostate Screening EpiSwitch (PSE) blood test significantly enhances overall detection accuracy for at-risk men, offering a rapid and minimally invasive diagnosis.
Scientists at Sanford Burnham Prebys have discovered a new treatment approach that can kill prostate cancer cells by targeting the PI5P4Kα enzyme. This finding has significant implications for addressing treatment resistance in prostate cancer and may lead to improved treatments for other cancers.
Researchers at Cedars-Sinai Cancer have developed a non-invasive test that can detect and profile prostate cancers in microscopic amounts. The test, known as the EV Digital Scoring Assay, has the potential to spare patients from unnecessary treatment-related side effects and direct them to effective therapies.
According to hyperfunction theory, menopause is also a disease. Aging is a quasi-programmed disease that can be partially treatable by rapamycin. The author suggests that slowing aging may delay the onset of diseases like prostate cancer, obesity, and hypertension.
A $1.1 million Department of Defense grant supports Augusta University research linking prostate cancer and cardiovascular diseases. Dr. Avirup Guha's research aims to investigate the aging process, exploring the role of nicotinamide adenine dinucleotide in this connection.
Researchers at St. Jude Children's Research Hospital used cryo-electron microscopy to capture the first 3D structure of SPOP, a protein mutated in prostate and endometrial cancers. The study revealed previously unknown interfaces that harbor cancer-causing mutations, shedding light on how SPOP drives cancer.
Researchers found a novel molecular player driving neuroendocrine prostate cancer progression. The discovery uncovers new avenues for treating this aggressive form of prostate cancer.
Researchers developed the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) questionnaire to identify key symptoms and side effects associated with radionuclide therapy. The tool aims to improve patient-centered care and guide treatment decisions for prostate cancer patients.
A new study by University Hospitals Seidman Cancer Center demonstrates that social determinants of health, not just race, significantly influence prostate cancer outcomes. The research, published in JAMA Network Open, found that accounting for social determinants reduced racial disparities in mortality rates.
A new prostate cancer therapy is being tested in clinical trials, targeting the treatment-resistant form of the disease. The therapy uses a drug called Abivertinib to block a specific protein that allows tumors to produce androgens, a goal of using more targeted treatments like TKIs.
A new study found that MRI-guided radiotherapy is more effective than CT-guided therapy in reducing side effects and improving quality of life for patients with localized prostate cancer. The trial involved 154 patients, who experienced fewer toxicities and better outcomes when treated with MRI guidance.
The American Cancer Society released its annual report on cancer facts and trends, showing a 33% drop in overall cancer mortality since 1991. However, prostate cancer incidence increased by 3% per year from 2014 to 2019, with advanced-stage disease diagnoses rising by 4-5% annually.
The meta-analysis of 47 studies and 1 million patients suggests a vital role for social determinants of health variables in developing strategies to achieve equity. Incorporating these variables can significantly impact prostate cancer–specific mortality and overall survival among men with prostate cancer.
Adding apalutamide to active surveillance for early-stage prostate cancer may lower the rate of positive biopsies, according to a preliminary clinical trial. Fifty-nine percent of patients had no evidence of residual cancer on immediate posttreatment biopsy.
PSMA PET/MRI successfully determines prostate cancer likelihood of return within two years after prostatectomy, aiding treatment decisions. High uptake in primary lesion and metastasis are associated with rapid recurrence.
A study by Wake Forest University School of Medicine found that primary care providers frequently order prostate cancer screening tests, even when they provide little value to patients. The research team analyzed data from the National Ambulatory Medicare Care Survey and found a significant increase in low-value screenings, such as PSA...
A study found that Medicare costs for metastatic prostate cancer increased significantly between 2007 and 2017, with average annual spending per patient rising from $28,311 to $37,055. The majority of the increase was attributed to new treatments under Medicare Part D, such as radium-223, sipuleucel-T, abiraterone, and enzalutamide.
The American Roentgen Ray Society has awarded the 2023 ARRS Gold Medal to Dr. Bernard F. King, Jr., MD, FACR, FSAR, in recognition of his distinguished service to radiology. Dr. King has made significant contributions to the field, including the development of contrast media recognition and treatment protocols.
A comprehensive genetic testing protocol increased patient compliance with recommended testing from 33.3% to 98.7%, while also reducing turnaround time for genetic test results.
Researchers characterized prostate cancer cell dynamics at single-cell resolution, revealing an expansion of intermediate cells that correlates with treatment resistance and poor clinical outcomes. A 5-gene signature associated with treatment resistance was also discovered.
A new study from Edith Cowan University found that a single bout of exercise can significantly suppress tumour growth in people with late-stage prostate cancer. The researchers observed increased levels of anti-cancer myokines after high-intensity exercise, which helped fight cancerous cells and stimulated anti-cancer processes.
Researchers have developed a comprehensive tool to predict prostate cancer risk, incorporating genetic and family history data. The algorithm aims to identify men at highest risk for targeted screening and diagnostic tests, reducing unnecessary tests for those at low risk.
A new diagnostic pathway for prostate cancer reduces the number of harmless tumors found during screening, halving the risk of overdiagnosis. This strategy involves using MRI to guide targeted tissue sampling, reducing the need for unnecessary biopsies and associated complications.
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
Researchers at IRB Barcelona have developed a new tool to block protein-protein interactions, a potential therapeutic approach for diseases such as prostate cancer. The synthetic molecules mimic the binding surface of proteins, offering high versatility and stability.
A recent study by Duke University researchers has identified key risk factors for Black men diagnosed with early-onset prostate cancer. Genetic variants and a family history of cancer are associated with an increased risk of developing the disease. The study's findings could help reduce racial disparities in prostate cancer outcomes.
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
Research emphasizes the importance of ethnically diverse prostate cancer genomics data and accessible genetic testing. Variations in genomic landscape of prostate cancer were observed in Chinese men compared to Western cohorts, with lower mutation rates in driver genes such as TP53 and PTEN.
Black and Hispanic men are underrepresented in prostate cancer clinical trials compared to their incidence rate. The representation of Black patients has remained consistently low over the past two decades.
A single drug compound attacks prostate cancer on several fronts by triggering immune cells to attack, helping them penetrate the tumor, and cutting off its ability to use testosterone as fuel. The study found that the drug activates anti-cancer T cells in a novel way and increases their ability to penetrate tumors.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A new treatment approach using surgery or radiation therapy has been shown to slow cancer progression in patients with solitary prostate cancer metastases. The study found that this approach, called metastasis-directed therapy (MDT), can delay the need for hormone-blocking treatments and improve survival rates.
A study found that top YouTube and TikTok videos on prostate cancer screening recommendations have low to moderate quality consumer health information. Black and Hispanic representation was underrepresented in most videos, and high-risk racial groups were not discussed adequately.
A novel radiopharmaceutical treatment targeting prostate-specific membrane antigen effectively shrinks prostate tumors in mice, with minimal impact on major organs. Researchers plan to launch a clinical trial for refractory prostate cancer patients in two years.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers developed a polygenic hazard score based on 290 genetic variants to predict genetic risk of lethal prostate cancer. The study analyzed nearly 591,000 men and found that the score adds considerably more information for individualized risk assessment, potentially benefiting high-risk men with accurate screening.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
The EXTEND trial found that combining metastasis-directed radiation therapy with intermittent hormone therapy improved progression-free survival in men with oligometastatic prostate cancer. The treatment also prolonged the time men could safely maintain normal testosterone levels, preserving their quality of life.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.
A phase III clinical trial confirms the safety and efficacy of a moderately shortened course of radiation therapy for men with high-risk prostate cancer. The study found no significant differences in survival rates, side effects, or recurrence between 5-week and 8-week radiation therapy.
A new analysis by UCLA Jonsson Comprehensive Cancer Center found that men with prostate cancer benefit from adding androgen deprivation therapy to radiation treatment. The study showed improved metastasis-free survival for patients receiving short-term ADT before or after radiation, especially in those receiving prostate-only RT.
A new study found that sexual side effects of cancer treatment are discussed less frequently with female patients, who are asked about their sexual health 1 in 10 times, compared to 9 in 10 men. The disparity is also observed in clinical trials nationwide.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
Researchers at Baylor College of Medicine discovered a novel approach to suppress the growth of therapy-resistant prostate cancer tumors. By enhancing GATA2 degradation, the study found marked suppression of tumor growth and castration resistance in animal models.
Scientists have identified two new epigenetic biomarkers that can predict the development of aggressive prostate cancer, enabling clinicians to develop more personalized treatment plans. The study used comprehensive molecular analysis of 185 biopsies from men with prostate cancer diagnosed between 1990 and 2000.